DEGLI UBERTI, Ettore
 Distribuzione geografica
Continente #
NA - Nord America 22.166
EU - Europa 7.625
AS - Asia 3.715
Continente sconosciuto - Info sul continente non disponibili 18
SA - Sud America 16
AF - Africa 6
OC - Oceania 6
Totale 33.552
Nazione #
US - Stati Uniti d'America 22.145
CN - Cina 2.528
DE - Germania 2.453
UA - Ucraina 1.930
TR - Turchia 1.117
IT - Italia 836
GB - Regno Unito 685
SE - Svezia 467
FI - Finlandia 442
RU - Federazione Russa 343
PL - Polonia 154
BE - Belgio 140
FR - Francia 93
IR - Iran 24
CZ - Repubblica Ceca 17
IN - India 17
NL - Olanda 16
EU - Europa 14
CA - Canada 13
IE - Irlanda 10
RO - Romania 10
VN - Vietnam 10
BR - Brasile 6
MA - Marocco 6
MX - Messico 5
A2 - ???statistics.table.value.countryCode.A2??? 4
AU - Australia 4
CH - Svizzera 4
PE - Perù 4
PT - Portogallo 4
AT - Austria 3
DK - Danimarca 3
EC - Ecuador 3
ES - Italia 3
HK - Hong Kong 3
BD - Bangladesh 2
CY - Cipro 2
GR - Grecia 2
HR - Croazia 2
HU - Ungheria 2
IQ - Iraq 2
JP - Giappone 2
KZ - Kazakistan 2
MD - Moldavia 2
NZ - Nuova Zelanda 2
AE - Emirati Arabi Uniti 1
AR - Argentina 1
BG - Bulgaria 1
CL - Cile 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
KR - Corea 1
MC - Monaco 1
MY - Malesia 1
NO - Norvegia 1
NP - Nepal 1
PA - Panama 1
PH - Filippine 1
PK - Pakistan 1
RS - Serbia 1
VE - Venezuela 1
Totale 33.552
Città #
Woodbridge 3.027
Fairfield 2.448
Jacksonville 2.158
Chandler 2.078
Houston 1.721
Ashburn 1.714
Ann Arbor 1.271
Wilmington 950
Seattle 938
Cambridge 747
Izmir 676
Nanjing 615
Beijing 545
Princeton 439
Addison 384
San Diego 275
Boardman 262
Shenyang 198
Milan 196
Nanchang 180
New York 164
Dearborn 163
Warsaw 153
Ferrara 135
Brussels 134
Hebei 134
Shanghai 114
Changsha 112
Bremen 109
Tianjin 107
Washington 107
Jiaxing 97
Jinan 79
Falls Church 69
Mountain View 67
San Mateo 62
Kunming 47
Norwalk 47
Ningbo 45
Redwood City 44
Helsinki 43
Zhengzhou 43
London 42
Carrara 40
Guangzhou 37
Auburn Hills 36
Tappahannock 36
Taizhou 33
Leawood 30
Orange 28
Düsseldorf 27
Des Moines 26
Indiana 25
Hefei 24
Philadelphia 24
Augusta 22
Verona 20
Hangzhou 19
Monmouth Junction 18
Ardabil 17
Lanzhou 15
Los Angeles 15
Brno 14
Changchun 13
Bologna 12
Ferrara di Monte Baldo 12
Haikou 11
Prescot 10
Redmond 10
Dong Ket 9
Hounslow 9
Rome 9
Chengdu 8
Kilburn 8
Mumbai 8
San Francisco 8
Walnut 8
Yellow Springs 8
Padova 7
Chicago 6
Dallas 6
Acton 5
Castelnuovo Rangone 5
Fuzhou 5
Munich 5
Tangier 5
Chiswick 4
Dublin 4
Edinburgh 4
Hanover 4
Jinhua 4
Lima 4
Pisa 4
Taiyuan 4
Waanrode 4
Andover 3
Caiazzo 3
Cordovado 3
Frankfurt am Main 3
Hebden Bridge 3
Totale 23.683
Nome #
SRC homology-2-containing protein tyrosine phosphatase-1 restrains cell proliferation in human medullary thyroid carcinoma 335
Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds 235
Magmas Overexpression Inhibits Staurosporine Induced Apoptosis in Rat Pituitary Adenoma Cell Lines 159
Igf-I influences everolimus activity in medullary thyroid carcinoma 158
Effect of Everolimus on Cell Viability in Nonfunctioning Pituitary Adenomas 156
Effect of deltorphin on pituitary-adrenal response to insulin-induced hypoglycemia and ovine corticotropin-releasing hormone in healthy man 154
Circadian profile of plasma calcitonin gene-related peptide in healthy man 151
Role of Ultrasonographic/Clinical Profile, Cytology, and BRAF V600E Mutation Evaluation in Thyroid Nodule Screening for Malignancy: A Prospective Study 151
Proposal for a novel management of indeterminate thyroid nodules on the basis of cytopathological subclasses 148
Recettori della somatostatina e carcinoma midollare della tiroide: prospettive future. 148
Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism 145
Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives. 140
ROLL technique application for Minimally-Invasive Radioguided Parathyroidectomy (MIRP) in Hyperparathyroidism (HPT) 139
Cyclooxygenase-2 inhibitors prevent the development of chemoresistance phenotype in a breast cancer cell line by inhibiting glycoprotein p-170 expression. 136
Increase in Peripheral CD3-CD56brightCD16- Natural Killer Cells in Hashimoto's Thyroiditis Associated with HHV-6 Infection 136
A novel germline CDKN1B mutation causing multiple endocrine tumors: clinical, genetic and functional characterization 135
Relevance of BRAF(V600E) Mutation Testing Versus RAS Point Mutations and RET/PTC Rearrangements Evaluation in the Diagnosis of Thyroid Cancer 133
Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non functioning pituitary adenomas by inhibiting Vascular Endothelial Growth Factor secretion. 132
Inhibition of epithelial growth factor receptor can play an important role in reducing cell growth and survival in adrenocortical tumors 132
Circadian rhythm of calcitonin gene-related peptide in uncomplicated essential hypertension 131
null 130
Predictors of Pituitary Dysfunction in Patients Surviving Ischemic Stroke 129
Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids 128
Cyclin D1 levels are involved in the resistance to m-TOR inhibitors in human bronchial carcinoids 127
Circadian rhythms of atrial natriuretic peptide, blood pressure and heart rate in normal subjects 126
Differences in blood pressure regulation of congestive heart failure, before and after treatment, correlate with changes in the circulating pattern of atrial natriuretic peptide 125
Protein Kinase C Delta restrains growth in ACTH-secreting pituitary adenoma cells 124
Consistent changes in the circadian rhythms of blood pressure and atrial natriuretic peptide in congestive heart failure 123
Atrial natriuretic peptide and circadian blood pressure regulation: clues from a chronobiological approach 122
Characterization of a deleted Y chromosome in a male with Turner stigmata 122
Involvement of PKCβ and PKCδ isoforms in TSH signaling pathway in thyroid cancer cell lines 121
Role of the serotonergic system in the genesis of vasovagal syncope. 120
Pituitary side effects of old and new drugs. 120
Dermorphin, a new opioid peptide, stimulates thyrotropin secretion in normal subjects 120
mTOR, AKT, p70S6K and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids 120
Cerebral aneurysm and acromegaly: a case report 119
Atrial strain is the main determinant of release of atrial natriuretic peptide 118
Evidence that enhancement of cholinergic tone increases basal plasma levels of calcitonin gene-related peptide in normal man 118
null 118
The cytotoxic effect of sunitinib on human bronchial carcinoid cell lines and primary cultures is counteracted by EGF and IGF-1 but not by VEGF 118
Post-partum thyroiditis - A clinical update 117
Stimulatory effect of dermorphin, a new synthetic potent opiate-like peptide, on human growth hormone secretion 117
Unexpected activation of pituitary-adrenal axis in healthy young and elderly subjects during somatostatin infusion 117
The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells. 117
Effect of ketanserin, an inhibitor of 5-HT2 receptors, on the aldosterone-stimulating action of metoclopramide 116
Circadian rhythms of atrial natriuretic peptide, renin, aldosterone, cortisol, blood pressure and heart rate in normal and hypertensive subjects 115
Early onset acromegaly associated with a novel deletion in CDKN1B 5'UTR region 115
Rare diseases in clinical endocrinology: a taxonomic classification system. 115
null 114
Proteasomes and RARS modulate AIMP1/EMAP II secretion in human cancer cell lines. 114
In vitro testing of new somatostatin analogs on pituitary tumor cells 114
VEGF autocrine secretion is enhanced by EGFR activation trough ERK1/2 phosphorylation in human adrenocortical carcinoma cell lines 114
null 113
Different levels of thyroglobulin mRNA in normal and neoplastic human thyroids 113
Radio-guided selective compartment neck dissection improves staging in papillary thyroid carcinoma: a prospective study on 345 patients with a 3-year follow-up. 113
Epidermal growth factor pathway as a possible target in the medical therapy of bronchial carcinoids 113
Magmas, a Gene Newly Identified as Overexpressed in Human and Mouse ACTH-Secreting Pituitary Adenomas, Protects Pituitary Cells from Apoptotic Stimuli 112
IGF-I Proliferative Effects Are Inhibited by Targeting PKC in Human Endocrine Tumor Cells 112
Functional characterization of a new deletion in CDKN1B 5'-UTR region 112
Cholinergic mediation in dermorphin-induced growth hormone secretion in man 112
RET mutation profile and variable clinical manifestations in a family with multiple endocrine neoplasia type 2A and Hirschsprung's disease 112
BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine needle aspiration biopsies. 112
null 111
Responses of plasma renin activity, aldosterone, adrenocorticotropin, and cortisol to dermorphin, a new synthetic potent opiate-like peptide, in man 111
Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression. 111
null 111
L’iperplasia surrenale congenita e la pubertà precoce 111
HHV-6A in vitro infection of thyrocytes and T cells alters the expression of miRNA associated to autoimmune thyroiditis 111
Should aip gene screening be recommended in family members of FIPA patients with R16H variant? 111
Somatostatin receptor subtype 1 selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line. 110
Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study. 110
mTOR mediated IGF1 proliferative effects on a rat pituitary GH/PRL secreting pituitary adenoma cell line 109
Progressive disruption of the circadian rhythm of melatonin in fatal familial insomnia 108
null 108
Iodine excess and hyperthyroidism 108
Time-dependent effect of isradipine on the nocturnal hypertension in chronic renal failure 107
Magmas, a Novel Over-Expressed Gene in Pituitary Rat Cell Lines and in Human Pituitary Adenomas: A New Pituitary Biomarker? 107
Effect of dermorphin on behavior and hippocampal electrical activity in rabbits 106
null 106
null 106
Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. 106
Dermorphin inhibits spinal nociceptive flexion reflex in humans 106
null 106
Virologic and immunologic evidence supporting an association between HHV-6 and Hashimoto’s thyroiditis 105
mTOR, p70S6K, AKT and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids 105
null 105
Prolactin-Releasing Activity of Dermorphin, a New Synthetic Potent Opiate-Like Peptide, in Normal Human Subjects 105
Does placebo lower blood pressure in hypertensive patients? A noninvasive chronobiological study 104
Therapeutic concentrations of mitotane (o,p'-DDD) inhibit thyrotroph cell viability and TSH expression and secretion in a mouse cell line model. 104
miR-15a and miR-16-1 down-regulation in pituitary adenomas 104
Changes of plasma calcitonin gene-related peptide levels in postmenopausal women 104
Growth hormone and skeletal muscle function 103
Growth hormone excess promotes breast cancer chemoresistance 103
null 103
Recettori della Somatostatina e Carcinoma Midollare della Tiroide: prospettive future. 102
null 102
null 102
Growth Hormone Enhances Breast Cancer Chemoresistance by Inhibiting JNK-Mediated Apoptosis 102
Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression 102
Prolactin and growth hormone responses to dermorphin in patients with prolactin-secreting pituitary adenoma 102
Totale 12.148
Categoria #
all - tutte 104.134
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 6.349
Totale 110.483


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20193.701 0 0 0 0 0 0 0 42 417 747 804 1.691
2019/20206.971 1.244 193 188 1.012 424 884 545 715 447 827 395 97
2020/20214.416 463 380 205 586 164 495 115 520 68 522 688 210
2021/20224.080 129 416 246 180 192 186 164 183 164 338 437 1.445
2022/20234.458 443 303 175 595 687 658 199 392 583 46 220 157
2023/20241.873 212 282 141 78 246 382 71 461 0 0 0 0
Totale 33.863